Cala Health Secures $50M Funding to Advance Wearable Therapy for Treating Tremors

**Cala Health Secures $50M Funding to Advance Wearable Therapy for Treating Tremors**

Cala Health, a pioneering medical technology company specializing in wearable neuromodulation therapies, has announced a significant milestone in its mission to transform the treatment of chronic diseases. The company recently secured $50 million in funding, a move that underscores the growing confidence in its innovative approach to addressing essential tremor and other movement disorders. This funding round is expected to accelerate the development and commercialization of Cala Health’s cutting-edge wearable therapy, offering new hope to millions of patients worldwide.

### Addressing a Critical Unmet Need

Essential tremor (ET) is the most common movement disorder, affecting an estimated 10 million people in the United States alone. Characterized by involuntary and rhythmic shaking, ET can severely impact a person’s ability to perform everyday tasks like eating, writing, or using a smartphone. While medications and surgical interventions exist, they are often associated with limited efficacy, significant side effects, or high costs, leaving many patients underserved.

Cala Health aims to bridge this gap with its innovative wearable therapy, Cala TAPS (Transcutaneous Afferent Patterned Stimulation). The device is designed to provide non-invasive, drug-free relief for patients suffering from tremors. By delivering electrical stimulation to the nerves in the wrist, the Cala TAPS therapy modulates neural circuits in the brain that are involved in tremor generation, offering a personalized and effective treatment option.

### The Technology Behind Cala TAPS

Cala TAPS represents a breakthrough in wearable neuromodulation technology. The device is worn like a wristband and uses advanced algorithms to tailor its electrical stimulation patterns to the unique tremor profile of each patient. This personalized approach ensures optimal efficacy while minimizing discomfort.

The therapy is controlled via a user-friendly mobile app, allowing patients to manage their treatment sessions conveniently. Clinical studies have demonstrated that Cala TAPS can significantly reduce tremor severity, improve quality of life, and enable patients to regain independence in their daily activities. Importantly, the therapy is non-invasive and reversible, making it a safer alternative to surgical procedures like deep brain stimulation.

### The $50 Million Funding Round

The $50 million funding round was led by a consortium of prominent investors, including new and existing stakeholders who recognize the transformative potential of Cala Health’s technology. The infusion of capital will be used to expand the company’s research and development efforts, scale manufacturing capabilities, and enhance its commercial footprint.

In addition to advancing its flagship Cala TAPS therapy, Cala Health plans to explore new applications of its wearable neuromodulation platform. The company is investigating potential treatments for other neurological and chronic conditions, such as Parkinson’s disease, epilepsy, and chronic pain, further broadening its impact on the healthcare landscape.

### A Growing Market for Wearable Therapies

Cala Health’s success comes at a time when the wearable medical device market is experiencing rapid growth. According to industry reports, the global wearable medical device market is projected to reach $139 billion by 2028, driven by advancements in sensor technology, artificial intelligence, and patient demand for non-invasive treatment options.

The company’s innovative approach aligns with broader trends in digital health and personalized medicine. By combining wearable technology with data-driven insights, Cala Health is not only addressing a critical unmet need but also setting a new standard for patient-centered care.

### The Road Ahead

With the new funding in place, Cala Health is well-positioned to accelerate its mission of empowering patients through innovative therapies. The company plans to expand access to Cala TAPS therapy by forging partnerships with healthcare providers, payers, and patient advocacy groups. Additionally, Cala Health is committed to conducting further clinical studies to validate the efficacy and safety of its technology across diverse patient populations.

The $50 million investment also signals a growing recognition of the importance of wearable neuromodulation as a viable treatment modality. As Cala Health continues to push the boundaries of what’s possible in wearable therapy, it is poised to make a lasting impact on the lives of patients suffering from tremors and other chronic conditions.

### Conclusion

Cala Health’s recent $50 million funding round marks a significant step forward in the fight against essential tremor and other movement disorders. By leveraging cutting-edge wearable technology, the company is redefining how chronic diseases are treated, offering patients a non-invasive, personalized, and effective solution. As the healthcare industry increasingly embraces digital and wearable innovations, Cala Health stands at the forefront of a new era in medical treatment, bringing hope and relief to millions around the world.